BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, Zhang X, Guo Z, Wu H, Sun L, Su G, Lin Q, Chen H. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy. Mol Pharm 2022. [PMID: 35917335 DOI: 10.1021/acs.molpharmaceut.2c00424] [Reference Citation Analysis]
2 Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther 2022. [PMID: 35373336 DOI: 10.1002/cpt.2598] [Reference Citation Analysis]
3 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Song W, Song Y, Li Q, Fan C, Lan X, Jiang D. Advances in aptamer-based nuclear imaging. Eur J Nucl Med Mol Imaging 2022. [PMID: 35394153 DOI: 10.1007/s00259-022-05782-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC. Eur J Nucl Med Mol Imaging 2021;48:2566-72. [PMID: 33452632 DOI: 10.1007/s00259-020-05177-z] [Reference Citation Analysis]
7 Hu J, Li H, Sui Y, Du J. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging 2021. [PMID: 34767047 DOI: 10.1007/s00259-021-05615-6] [Reference Citation Analysis]
8 Yang G, Gao H, Luo C, Zhao X, Luo Q, Shi J, Wang F. Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αvβ3-Targeted Radionuclide Therapy. Pharmaceutics 2022;14:1327. [DOI: 10.3390/pharmaceutics14071327] [Reference Citation Analysis]